Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures
about
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activityDifferential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNRHigh-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolateResistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Uukuniemi Phlebovirus assembly and secretion leave a functional imprint on the virion glycomeConsistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaquesReplication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesDetermination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesUse of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variantAlthough macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virusThe long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.Exclusive Decoration of Simian Immunodeficiency Virus Env with High-Mannose Type N-Glycans Is Not Compatible with Mucosal Transmission in Rhesus MacaquesIdentification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques.Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.Macrophage-derived simian immunodeficiency virus exhibits enhanced infectivity by comparison with T-cell-derived virus.
P2860
Q21076115-770A5FD9-ACE0-48BB-8D17-F86B9B7D226BQ24541155-76A99F9E-63EC-4BE1-BB39-A8FC2828C569Q30570557-FE0B3464-71AC-4A84-A3CC-49754FE59974Q33348658-59C4BC10-E4E4-4323-B71E-07780768ED17Q33807535-51A4213E-B016-406C-A18A-227FAC6F1A7EQ33808774-2866389A-2F30-4150-A3EE-A5546BA2D2CDQ33811940-45661700-EFA9-4086-B172-E98C4DE6EDC8Q33827027-B9349A25-ACC6-41BF-8894-69EA6B175262Q33839456-73366D64-651A-4D25-9016-09CE31AEA4FFQ34059387-5D7BA3EE-A4B0-49F4-8865-9DC036F5F0ACQ34301728-F528859F-AD8E-4B37-8732-904792977A88Q34357068-2DAF0209-3987-4843-9AD9-B5BEEAE4168DQ34391256-AEB0D696-C2E1-484C-B8C2-F0278C22ECBFQ34465510-A24BF29B-2377-4F06-BE77-5743994B0F4EQ34970873-B2F83DF8-1330-4165-94C2-F0021184970BQ35690523-6E394F1B-7938-4205-A513-5FE3B8E315B6Q35876561-0851274A-38EE-41B9-BF2A-BA0677F0C056Q36099083-FE2B4EC1-AEAC-4ACD-A70F-A88957145EC7Q36707305-18206D76-ECF2-4AFB-A0E9-40385C537F48Q37152680-0553F741-6B1C-4964-9BEE-0C86428C51D8Q37428017-D9A5B8CA-157A-45A4-82D2-367344FB88E0Q38836455-EFB05ADF-EA6D-4005-B44C-63518ADFA22FQ39615794-8598C46D-2E04-45C6-A692-94740844491EQ40113932-6675F5F3-98F4-46EC-9F98-AF9E10985E58Q41914053-74BF88C5-FBCE-40CC-A454-1AEC0C22E81A
P2860
Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Differential glycosylation, vi ...... hocyte and macrophage cultures
@ast
Differential glycosylation, vi ...... hocyte and macrophage cultures
@en
type
label
Differential glycosylation, vi ...... hocyte and macrophage cultures
@ast
Differential glycosylation, vi ...... hocyte and macrophage cultures
@en
prefLabel
Differential glycosylation, vi ...... hocyte and macrophage cultures
@ast
Differential glycosylation, vi ...... hocyte and macrophage cultures
@en
P2093
P2860
P1433
P1476
Differential glycosylation, vi ...... hocyte and macrophage cultures
@en
P2093
P2860
P304
P407
P577
1996-09-01T00:00:00Z